|
Name |
Gibberellin A53
|
| Molecular Formula | C20H28O5 | |
| IUPAC Name* |
(1S,2S,3S,4R,8S,9S,12S)-12-hydroxy-4,8-dimethyl-13-methylidenetetracyclo[10.2.1.01,9.03,8]pentadecane-2,4-dicarboxylic acid
|
|
| SMILES |
C[C@@]12CCC[C@@]([C@H]1[C@@H]([C@]34[C@H]2CC[C@](C3)(C(=C)C4)O)C(=O)O)(C)C(=O)O
|
|
| InChI |
InChI=1S/C20H28O5/c1-11-9-19-10-20(11,25)8-5-12(19)17(2)6-4-7-18(3,16(23)24)14(17)13(19)15(21)22/h12-14,25H,1,4-10H2,2-3H3,(H,21,22)(H,23,24)/t12-,13+,14-,17-,18+,19-,20-/m0/s1
|
|
| InChIKey |
CZEMYYICWZPENF-VOLTXKGXSA-N
|
|
| Synonyms |
Gibberellin A53; 51576-08-0; GA53; (1S,2S,3S,4R,8S,9S,12S)-12-hydroxy-4,8-dimethyl-13-methylidenetetracyclo[10.2.1.01,9.03,8]pentadecane-2,4-dicarboxylic acid; gibberellin 53; CHEBI:27433; DTXSID20331540; LMPR0104170007; (1S,2S,3S,4R,8S,9S,12S)-12-hydroxy-4,8-dimethyl-13-methylidenetetracyclo[10.2.1.0(1,9).0(3,8)]pentadecane-2,4-dicarboxylic acid; C06094; Q27103126; (1alpha,4aalpha,4bbeta,10beta)-7-hydroxy-1,4a-dimethyl-8-methylenegibbane-1,10-dicarboxylic acid; 7alpha-hydroxy-1beta,4a-dimethyl-8-methylidene-4aalpha,4bbeta-gibbane-1alpha,10beta-dicarboxylic acid
|
|
| CAS | 51576-08-0 | |
| PubChem CID | 440914 | |
| ChEMBL ID | NA |
Chemical Classification: |
|
|
|---|
| Endophyte ID | Endophyte Name | Family | Genus | Taxonomy ID | GenBank ID | Closest GenBank ID | Reference | |
|---|---|---|---|---|---|---|---|---|
| Endophyte ID | Endophyte Name | Family | Genus | Taxonomy ID | GenBank ID | Closest GenBank ID | Reference |
| Bioactivity Name | Target ID | Target Name | Target Type | Target Organism | Target Organism ID | Potency of Bioactivity | Activity Type | Value | Unit | Endophyte ID | Endophyte Name | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Bioactivity Name | Target ID | Target Name | Target Type | Target Organism | Target Organism ID | Potency of Bioactivity | Activity Type | Value | Unit | Endophyte ID | Endophyte Name |
| Molecular Weight: | 348.4 | ALogp: | 2.2 |
| HBD: | 3 | HBA: | 5 |
| Rotatable Bonds: | 2 | Lipinski's rule of five: | Accepted |
| Polar Surface Area: | 94.8 | Aromatic Rings: | 4 |
| Heavy Atoms: | 25 | QED Weighted: | 0.659 |
| Caco-2 Permeability: | -6.051 | MDCK Permeability: | 0.00003460 |
| Pgp-inhibitor: | 0 | Pgp-substrate: | 0.119 |
| Human Intestinal Absorption (HIA): | 0.007 | 20% Bioavailability (F20%): | 0.066 |
| 30% Bioavailability (F30%): | 0.014 |
| Blood-Brain-Barrier Penetration (BBB): | 0.382 | Plasma Protein Binding (PPB): | 47.24% |
| Volume Distribution (VD): | 0.354 | Fu: | 44.31% |
| CYP1A2-inhibitor: | 0.003 | CYP1A2-substrate: | 0.893 |
| CYP2C19-inhibitor: | 0.008 | CYP2C19-substrate: | 0.165 |
| CYP2C9-inhibitor: | 0.01 | CYP2C9-substrate: | 0.08 |
| CYP2D6-inhibitor: | 0.01 | CYP2D6-substrate: | 0.1 |
| CYP3A4-inhibitor: | 0.379 | CYP3A4-substrate: | 0.02 |
| Clearance (CL): | 1.487 | Half-life (T1/2): | 0.239 |
| hERG Blockers: | 0.008 | Human Hepatotoxicity (H-HT): | 0.599 |
| Drug-inuced Liver Injury (DILI): | 0.036 | AMES Toxicity: | 0.018 |
| Rat Oral Acute Toxicity: | 0.198 | Maximum Recommended Daily Dose: | 0.332 |
| Skin Sensitization: | 0.066 | Carcinogencity: | 0.554 |
| Eye Corrosion: | 0.398 | Eye Irritation: | 0.144 |
| Respiratory Toxicity: | 0.979 |
| Similar NPs | Similar Drugs | ||||||
|---|---|---|---|---|---|---|---|
| NPs ID | NPs 2D Structure | Similarity Score | TTD ID | Drug 2D Structure | Similarity Score | ||
| ENC002541 | ![]() |
0.529 | D01CKY | ![]() |
0.283 | ||
| ENC000143 | ![]() |
0.500 | D0R7JT | ![]() |
0.273 | ||
| ENC002556 | ![]() |
0.483 | D0IX6I | ![]() |
0.266 | ||
| ENC002542 | ![]() |
0.467 | D0KR5B | ![]() |
0.266 | ||
| ENC003143 | ![]() |
0.463 | D00HWO | ![]() |
0.265 | ||
| ENC002902 | ![]() |
0.452 | D0I2SD | ![]() |
0.262 | ||
| ENC005547 | ![]() |
0.452 | D0X4RS | ![]() |
0.259 | ||
| ENC003162 | ![]() |
0.425 | D0Q6NZ | ![]() |
0.255 | ||
| ENC001844 | ![]() |
0.409 | D04GJN | ![]() |
0.250 | ||
| ENC002923 | ![]() |
0.390 | D08TEJ | ![]() |
0.246 | ||